Eli Lilly announced on Tuesday, September 23, 2025, that it will build a $6.5 billion manufacturing plant at Generation Park in Houston, Texas. The facility will focus on producing the company’s first oral GLP‑1 receptor agonist, orforglipron, and is expected to be operational within five years.
The new site is the second of four U.S. manufacturing plants Lilly plans to open this year as part of a $27 billion investment announced in February. The Houston plant will create 615 high‑wage jobs for engineers, scientists, and operations staff, and will generate an additional 4,000 construction jobs during its build‑out.
By bringing orforglipron production in‑house, Lilly aims to secure a reliable supply chain for its next‑generation obesity and type‑2 diabetes therapy, reduce dependence on overseas manufacturing, and accelerate the drug’s global launch. The investment underscores Lilly’s strategy to scale production of its high‑growth incretin portfolio while expanding its domestic manufacturing footprint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.